| ²é¿´: 2321 | »Ø¸´: 17 | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
lgslgwlgsľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
¡¾×ªÌû¡¿»ªÈË¿ÆÑ§¼Ò·¢ScienceÎÄÕ»ñÍ»ÆÆÐÔÑо¿³É¹û ÒÑÓÐ15È˲ÎÓë
|
|||
|
»ªÈË¿ÆÑ§¼Ò·¢ScienceÎÄÕ»ñÍ»ÆÆÐÔÑо¿³É¹û À´×ÔNIHÃÀ¹ú¹ú¼Ò¹ýÃôÓ봫Ⱦ²¡Ñо¿Ëù(NIAID)£¬¹þ·ðҽѧԺµÈ´¦µÄÑо¿ÈËÔ±·¢ÏÖÁËÁ½ÖÖ¿É·ÀÖ¹¸÷ÖÖ°¬×̲¡²¡¶¾(HIV)¸ÐȾÓë·±Ö³µÄÖкͿ¹Ì壬ÕâЩ¿¹ÌåÄܹ»ÓëÒ»×éHIV-1·ÖÀëÖêÖеÄ90%ÒÔÉϵIJ¡¶¾Öê½áºÏ²¢ÖкÍËüÃÇ¡£ÕâÏîÖØÒªµÄÑо¿³É¹û¹«²¼ÔÚScienceÔÓÖ¾ÉÏ£¬Í¬ÆÚScienceÔÓÖ¾ÉÏÁ½ÆªÎÄÕÂÏêϸ½éÉÜÁËÕâÖÖ¿¹Ìå¡£ ÆäÖÐһƪÎÄÕµĵÚÒ»×÷ÕßÖ®Ò»ÊÇĿǰÔÚÃÀ¹ú¹ú¼ÒÎÀÉúÑо¿ÔºÒßÃçÑо¿ÖÐÐÄ´Óʰ¬×̲¡ÒßÃçÑо¿¹¤×÷µÄÖÜͬÇ첩ʿ£¬ËûÔøÔÚNature·âÃæÉÏ·¢±íÎÄÕ£¬»ñµÃÁËÒ»¸öHIV£¨ÈËÃâÒßȱÏݲ¡¶¾£©°üĤµ°°×gp120Í»±äϵ£¬²¢È·¶¨ÁËÆäÖÐÖкͿ¹Ì壨neutralizing antibody£©b12µÄ½á¹¹£¬ÎªÒÖÖÆHIV-1°Ð¶¨ÕâÒ»ÇøÓò¿¹ÌåÒ©ÎïÑз¢ÒÔ¼°HIV»úÖÆÑо¿ÌṩÁËÍ»ÆÆÐÔµÄÑо¿³É¹û¡£ ×Ô´ÓÈËÀà1980Äê´ú³õ·¢ÏÖ°¬×̲¡ÒÔÀ´£¬È«Çò´óÔ¼ÒÑÓÐ6000ÍòÈ˸ÐȾÁ˰¬×̲¡²¡¶¾¡£°¬×̲¡µÄÔ¤·ÀºÍÖÎÁÆÒ»Ö±ÊÇÈ«Çòҽѧ¿ÆÑ§¼ÒÂŹ¥²»¿ËµÄÄÑÌ⣬µ«ÊÇ×ÔÈ¥ÄêÒÔÀ´£¬°¬×̲¡ÒßÃçÑо¿»ñµÃÁ˳¤×ãµÄ½øÕ¹£¬±ÈÈçÈ¥Äê9Ô£¬ÃÀ¹úºÍÌ©¹úÑо¿ÈËÔ±Ðû²¼»ñµÃÊÀ½çÉϵÚÒ»ÖÖ¾ßÓÐÒ»¶¨ÃâÒßЧ¹ûµÄ°¬×̲¡ÒßÃç¡£ ÔÚ×îеÄÕâÁ½ÆªÎÄÕÂÖУ¬Ñо¿ÈËÔ±Ôò±¨µÀÁËÁ½ÖÖÒÔǰδ֪µÄÖкͿ¹Ì壬ÕâЩ¿¹ÌåÄܹ»ÓëÒ»×éHIV-1·ÖÀëÖêÖеÄ90%ÒÔÉϵIJ¡¶¾Öê½áºÏ²¢ÖкÍËüÃÇ¡£Ñо¿ÈËÔ±ÈÏΪ¸Ã×éHIV-1·ÖÀëÖ꺸ÇÁËËùÓÐÖ÷ÒªµÄÕýÔÚÁ÷ÐеÄHIV-1»ùÒòÑÇÐÍ£¬ÕâЩ¿¹Ìå¿É°ïÖúÈËÃÇÔÚδÀ´Éè¼Æ³öÓÐЧµÄHIVÒßÃç¡£ µÚһƪÎÄÕÂÖУ¬Ñо¿ÈËÔ±Ìá³ö£¬´ó¶àÊýµÄÆäËü¹ãÆ×ÖкͿ¹Ìå¶ÔHIVµÄ°üĤµ°°×¾ßÓÐÌØÒìÐÔ£¬ÕâЩµ°°×ͨ³£Óë±ê°Ðϸ°û±íÃæµÄCD4ÊÜÌå½áºÏ£¬Òò´ËÑо¿ÈËÔ±¶ÔÊܵ½¸ÐȾ¸öÌåÖеÄÓë¸ÃCD4²¿Î»½áºÏµÄ×ÔÈ»·¢ÉúµÄ¿¹Ìå½øÐÐÁËÑо¿¡£Ñо¿ÈËÔ±½Ó×Å·ÖÀë³öÁ˲úÉúÕâЩ¿¹ÌåµÄ¸öÌåBϸ°û²¢·¢ÏÖÁ˸ßÇ¿¶ÈµÄHIV-1µÄÖкͿ¹Ìå¡£ ѰÕÒ¿ÉÖкÍÖÚ¶à°¬×̲¡²¡¶¾¾úÖêµÄµ¥¸ö¿¹Ìåһֱʮ·ÖÀ§ÄÑ£¬ÕâÊÇÒòΪÕâÀಡ¶¾Äܲ»¶Ï¸Ä±ä×ÔÉí±íÃæµÄµ°°×À´¡°ÃɱΡ±ÃâÒßϵͳ£¬´Ó¶ø³É¹¦ÈëÇÖÈËÌå¡£µ«¼´Ê¹Èç´Ë£¬¿ÆÑ§¼ÒÈÔȻȷ¶¨Á˰¬×̲¡²¡¶¾±íÃæÐ¡²¿·Ö¼¸ºõ²»±äµÄÇøÓò£¬ÈçÃûΪCD4µÄ½áºÏ²¿Î»¡£VRC01ºÍVRC02¿¹Ìå¾Í¿É¸½×ÅÔÚÎȶ¨µÄCD4ÇøÓòÄÚ£¬×èÖ¹²¡¶¾¡°´îÉÏ¡±ÈËÌåÃâÒßϸ°û£¬¶øÕâÒ²½âÊÍÁË£¬ÎªÊ²Ã´´ËÁ½ÖÖп¹ÌåÄܹ»Öк͸ߴï90%µÄ°¬×̲¡²¡¶¾¾úÖê¡£ ÁíÍâһƪÎÄÕÂÖУ¬Ñо¿ÈËÔ±·ÖÎöÁËб»·¢ÏÖ¿¹ÌåÖ®Ò»£¨VRC01£©µÄ¾§Ìå½á¹¹£¬¸Ã¿¹ÌåÕý´¦ÓÚHIV-1 °üĤµ°°×µÄÒ»¸ö¸´ºÏÎïÖС£Ñо¿ÈËÔ±ÈÏΪVRC01¿É²¿·ÖÄ£ÄâCD4 ÊÜÌåÓë¸Ã²¡¶¾°üĤµ°°×µÄÏ໥×÷Ó㬵«VRC01±¾ÉíµÄ¶¨Î»ÊǾ۽¹ÓÚÒ»¸öÔÚ²»Í¬µÄ²¡¶¾ÖêÖж¼²»»á±äµÄ²¿Î»£¬Õâ¿ÉÒÔ½âÊÍÆäΪʲô¾ßÓйãÆ×µÄÖкÍÄÜÁ¦¡£ VRC01¿¹ÌåÕýÊÇÒÔÕâÖÖ·½·¨À´ÖкͲ¡¶¾£¬²¢ÖÐ¶ÏÆäÖÂÃüÐÔÖ²¡Á¦µÄ¡£ ¸ù¾ÝÕâЩÑо¿³É¹û£¬Ñо¿ÈËÔ±¿ÉÒÔ»ùÓÚ¶Ô²¡¶¾½á¹¹µÄ³ä·ÖÀí½â£¬ÀûÓ÷Ö×ÓÉ豸ÔÚ°¬×̲¡²¡¶¾Íâ±í¾«È·¶¨Î»²¡¶¾Ò×Êܹ¥»÷µÄλÖ㬲¢ÕÒµ½¸½×ÅÔÚÕâЩ±¡ÈõµãÉÏ¡¢¿ÉÓÐЧ×èÖ¹²¡¶¾¸ÐȾ½¡¿µÏ¸°ûµÄ¿¹Ìå¡£ ÔÎÄÕªÒª£º Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1¨Cinfected subjects, but the virologic basis of their neutralization remains poorly understood. We used knowledge of HIV-1 envelope (Env) structure to develop antigenically resurfaced glycoproteins specific for the structurally conserved site of CD4 receptor binding. These probes were used to identify sera with NAbs to the CD4-binding site (CD4bs) and to isolate individual B cells from such an HIV-1¨Cinfected donor. By expressing immunoglobulin genes from individual cells, we identified three monoclonal antibodies, including a pair of somatic variants that neutralized over 90% of circulating HIV-1 isolates. Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of gp120, an important insight for future HIV-1 vaccine design. (http://www.ebiotrade.com/) http://www.ebiotrade.com/newsf/2010-7/2010719173036450.htm |
» ²ÂÄãϲ»¶
310Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁÏÓ뻯¹¤328·Öµ÷¼Á
ÒѾÓÐ8È˻ظ´
318Ò»Ö¾Ô¸¼ªÁÖ´óѧÉúÎïÓëÒ½Ò© Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸ÄÏ¿ª´óѧ0710ÉúÎïѧ359Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ4È˻ظ´
327Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
309Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸ÄϺ½ 335·Ö | 0856 | GPA 4.07 | ÓпÆÑоÀú
ÒѾÓÐ8È˻ظ´
Çó»¯Ñ§µ÷¼Á
ÒѾÓÐ5È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¹ØÓÚ¹ú²ú²©Ê¿ÊÇ·ñÔÙ¶ÁÒ»¸öº£ÍⲩʿѧλµÄһЩÏë·¨ºÍÀ§»ó
ÒѾÓÐ126È˻ظ´
NatMater×îÐÂÎÄÕ£º¿ÆÑ§¼ÒÑÐÖÆ¿É×ÔÐÐ×éװ΢ÐÍ´ÅÁ£»úÆ÷ÈË
ÒѾÓÐ7È˻ظ´
[Science]¿ÆÑ§¼Ò·¢ÏÖ»¯Ñ§·´Ó¦ÐÂÐÍÇý¶¯Á¦
ÒѾÓÐ11È˻ظ´
¡¾·ÖÏí¡¿Ê®¶þ뻪ÈË¿ÆÑ§¼ÒÈëѡȫÇò¶¥¼âÒ»°Ù»¯Ñ§¼Ò°ñµ¥
ÒѾÓÐ84È˻ظ´
Çë¸øÍ¶Nature&ScienceµÄÄêÇáÈ˸ö¹ÄÀø»·¾³£¡
ÒѾÓÐ55È˻ظ´
daijiangtao
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 12 (СѧÉú)
- ½ð±Ò: 5982.2
- É¢½ð: 20
- ºì»¨: 2
- Ìû×Ó: 1762
- ÔÚÏß: 628.4Сʱ
- ³æºÅ: 1058621
- ×¢²á: 2010-07-16
- ÐÔ±ð: GG
- רҵ: ¿ØÖÆÀíÂÛÓë·½·¨
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
| ÖµµÃÎÒÃÇÉî˼°¡£¬Ôõô¹úÄÚºÜÄÑ×ö³öÕâÑùµÄ³É¼¨°¡¡£ |
8Â¥2010-07-21 18:23:54
ÙþÁÁµí·Ûø
ר¼Ò¹ËÎÊ (ÖªÃû×÷¼Ò)
ÉúÎï´ó·Ö×Ó½µ½âø
-

ר¼Ò¾Ñé: +248 - BioEPI: 73
- Ó¦Öú: 257 (´óѧÉú)
- ¹ó±ö: 0.272
- ½ð±Ò: 19479.4
- É¢½ð: 1704
- ºì»¨: 121
- Ìû×Ó: 6591
- ÔÚÏß: 2779.1Сʱ
- ³æºÅ: 856414
- ×¢²á: 2009-09-25
- ÐÔ±ð: GG
- רҵ: »·¾³Î¢ÉúÎïѧ
- ¹ÜϽ: ΢ÉúÎï

2Â¥2010-07-20 13:07:10
1949stone
ÈÙÓþ°æÖ÷ (ÖªÃû×÷¼Ò)
º£Äɰٴ¨
- Ó¦Öú: 95 (³õÖÐÉú)
- ¹ó±ö: 2.38
- ½ð±Ò: 2633.7
- É¢½ð: 3394
- ºì»¨: 177
- ɳ·¢: 8
- Ìû×Ó: 9831
- ÔÚÏß: 2692.8Сʱ
- ³æºÅ: 765987
- ×¢²á: 2009-05-08
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
- ¹ÜϽ: ·Ö×ÓÉúÎï
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
|
»ªÈË ÒÔǰÊÇÖйúÈË »ò׿ÉÏÓÐÈËÊÇÖйúÈË µ«ËûÏÖÔÚ²»ÊÇÖйúÈË |

3Â¥2010-07-20 15:37:58
ÙþÁÁµí·Ûø
ר¼Ò¹ËÎÊ (ÖªÃû×÷¼Ò)
ÉúÎï´ó·Ö×Ó½µ½âø
-

ר¼Ò¾Ñé: +248 - BioEPI: 73
- Ó¦Öú: 257 (´óѧÉú)
- ¹ó±ö: 0.272
- ½ð±Ò: 19479.4
- É¢½ð: 1704
- ºì»¨: 121
- Ìû×Ó: 6591
- ÔÚÏß: 2779.1Сʱ
- ³æºÅ: 856414
- ×¢²á: 2009-09-25
- ÐÔ±ð: GG
- רҵ: »·¾³Î¢ÉúÎïѧ
- ¹ÜϽ: ΢ÉúÎï
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
scelab:ͬ¸Ð°¡~~~ 2010-07-20 23:43:00
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
scelab:ͬ¸Ð°¡~~~ 2010-07-20 23:43:00
| Õâ¾Íû±ØÒªÕâôעÒâÁË£¬ÔÚÎÒÑÛÖÐÊÀ½çÉÏÖ»ÓÐÈýÖÖ¹ú¼®£ºÖйú£¬ÈÕ±¾ºÍÍâ¹ú£¬ËùνµÄ»ªÈ˲»ÊÇÖйúÈË£¬ÊÇÍâ¹úÈË£¬´ïµ½µÄ³É¾Í²»ÊôÓÚÖйú£¬ÖйúÈËÒÔ´ËΪÈÙÊÇ´¿´âYY¡£ |

4Â¥2010-07-20 20:06:07














»Ø¸´´ËÂ¥